 Gain Therapeutics, Inc. NASDAQ: GANX shares were trading higher Wednesday after the company presented positive data on two of its lead compounds. What Happened: Bethesda, Maryland-based Gain announced positive data from a preclinical study evaluating two of its compounds, GT-02287 and GT-02329, which are being evaluated for the treatment of Gaucher and GBA1 Parkinsons disease. 